45.32

2.95% -1.4411

Protagonist Therapeutics Inc (PTGX)

Overview News Price History Option Chain Financials Why PTGX Down? Discussions Forecast

Protagonist Therapeutics Inc stock is traded at $45.32, with a volume of 172.70K. It is down -2.95% in the last 24 hours and up +2.28% over the past month. Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Previous Close:

$46.76

Open:

$47.15

24h Volume:

172.70K

Relative Volume:

0.30

Market Cap:

$2.70B

Revenue:

$45.48M

Net Income/Loss:

$162.11M

P/E Ratio:

-16.91

EPS:

-2.68

Net Cash Flow:

$-64.16M

1W Performance:

-6.30%

1M Performance:

+2.28%

6M Performance:

+73.94%

1Y Performance:

+172.55%

1-Day Range:

$44.92

$47.31

1-Week Range:

$44.92

$48.30

52-Week Range:

$14.78

$48.89

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name

Protagonist Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(510) 474-0170

Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Employee

125

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

PTGX's Discussions on Twitter

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-25-23	Resumed	Jefferies	Buy
Aug-25-22	Initiated	JMP Securities	Mkt Outperform
Feb-11-22	Initiated	BTIG Research	Buy
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral
May-24-21	Initiated	JMP Securities	Mkt Outperform
May-24-21	Initiated	Northland Capital	Outperform
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight
Sep-18-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Initiated	Jefferies	Buy
May-18-20	Reiterated	H.C. Wainwright	Buy
Jul-08-19	Initiated	H.C. Wainwright	Buy
May-09-19	Upgrade	Stifel	Hold → Buy
Dec-06-18	Initiated	Nomura	Buy
Jan-29-18	Initiated	Stifel	Buy
Jul-21-17	Initiated	BTIG Research	Buy

View All

Protagonist Therapeutics Inc Stock (PTGX) Latest News

04:18 AM

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World

04:18 AM

03:21 AM

Vanguard Group Inc's Strategic Acquisition in Protagonist Therap - GuruFocus.com

03:21 AM

Nov 04, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Given Outperform Rating at Wedbush - MarketBeat

Nov 04, 2024

Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $52.83 - Defense World

Nov 04, 2024

Nov 03, 2024

State of Alaska Department of Revenue Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 03, 2024

Nov 02, 2024

28,500 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Louisiana State Employees Retirement System - MarketBeat

Nov 02, 2024

Nov 01, 2024

Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 353% over 5 years despite pulling back 3.0% in the past week - Simply Wall St

Nov 01, 2024

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Nov 01, 2024

Oct 29, 2024

Allspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Oct 29, 2024

Allspring Global Investments Holdings LLC Buys 103,414 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Oct 29, 2024

Oct 28, 2024

Protagonist Therapeutics stock hits 52-week high at $48.34 By Investing.com - Investing.com South Africa

Oct 28, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighHere's What Happened - MarketBeat

Oct 28, 2024

Protagonist Therapeutics stock hits 52-week high at $48.34 - Investing.com India

Oct 28, 2024

Cavalier Investments LLC Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Oct 28, 2024

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Short Interest Update - MarketBeat

Oct 28, 2024

Cwm LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Oct 28, 2024

Oct 24, 2024

Moody Aldrich Partners LLC Sells 14,928 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Oct 24, 2024

Bleakley Financial Group LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Oct 24, 2024

(PTGX) Investment Report - Stock Traders Daily

Oct 24, 2024

Oct 19, 2024

Swedbank AB Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Oct 19, 2024

Oct 18, 2024